ICP-332, a highly selective Tyrosine Kinase 2 (TYK2) inhibitor, achieved superior EASI-75 responses (64%) compared to placebo (8%) at just 4 weeks.
Treatment led to a remarkable 78.2% reduction in EASI scores for the 80-mg cohort, signaling rapid clinical onset.
The safety profile was characterized by mild-to-moderate treatment-emergent adverse events (TEAEs), with no reported severe systemic complications typical of non-selective JAK inhibitors.
Selective TYK2 inhibition represents a targeted therapeutic strategy that may bypass the hematologic and metabolic side effects associated with pan-JAK inhibition.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.